Literature DB >> 949685

Locally recurrent carcinoma of the breast. Results of radiation therapy.

F C Chu, F J Lin, J H Kim, S H Huh, C J Garmatis.   

Abstract

Local and regional recurrences are frequent problems in breast cancer management. Radiation therapy is effective in producing long term remission. This study evaluates the results of radiation therapy of 215 patients with recurrent disease limited to the chest wall and/or regional lymph node areas. The local results showed complete control in 67% of cases (mean and median durations 32 months and 22 months, respectively), partial control in 24% of cases (mean and median 11 and 8 months, respectively) and no control in the remaining 9%. The radiation dose recommended for the treatment of recurrent mammary carcinoma is 5000 rads in 5 weeks for relatively small lesions. Supplementary local doses of 500-1000 rads in 1 week may be given to bulky lesions as necessary for residual disease. Although local relapse indicates a poor prognosis, it is by no means totally hopeless. Of 215 patients treated 44 (21%) survived 5 years and 10 (5%) survived 10 years following radiation therapy of recurrent disease. There were seven patients, or 3%, who were free of cancer at 5 to 15 years. Radiation therapy was valuable in controlling local lesions, and thus, in improving quality of survival, even in those patients who eventually died of metastatic disease.

Entities:  

Mesh:

Year:  1976        PMID: 949685     DOI: 10.1002/1097-0142(197606)37:6<2677::aid-cncr2820370616>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Results of salvage surgery for mammary recurrence following breast-conserving therapy.

Authors:  J M Kurtz; R Amalric; H Brandone; Y Ayme; J M Spitalier
Journal:  Ann Surg       Date:  1988-03       Impact factor: 12.969

2.  Role of radiotherapy in the management of breast cancer.

Authors:  P P Kumar
Journal:  J Natl Med Assoc       Date:  1977-11       Impact factor: 1.798

Review 3.  The role of post-operative radiotherapy in the treatment of operable breast cancer.

Authors:  G F Beadle; J R Harris
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

Review 4.  Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data.

Authors:  Timothy M Zagar; James R Oleson; Zeljko Vujaskovic; Mark W Dewhirst; Oana I Craciunescu; Kimberly L Blackwell; Leonard R Prosnitz; Ellen L Jones
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 5.  Patterns of metastasis and natural courses of breast carcinoma.

Authors:  Y T Lee
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

6.  Treatment of primary breast cancer without mastectomy. The Los Angeles community experience and review of the literature.

Authors: 
Journal:  Ann Surg       Date:  1986-08       Impact factor: 12.969

Review 7.  Patterns of recurrence in Western and Japanese women with breast cancer.

Authors:  M A Chaudary
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

8.  Dose volume histogram analysis and comparison of different radiobiological models using in-house developed software.

Authors:  Arun S Oinam; Lakhwant Singh; Arvind Shukla; Sushmita Ghoshal; Rakesh Kapoor; Suresh C Sharma
Journal:  J Med Phys       Date:  2011-10

Review 9.  Preserving the legacy of reirradiation: A narrative review of historical publications.

Authors:  Carsten Nieder; Johannes A Langendijk; Matthias Guckenberger; Anca L Grosu
Journal:  Adv Radiat Oncol       Date:  2017-02-28

10.  RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.

Authors:  Tyler J W Robinson; Jeff C Liu; Frederick Vizeacoumar; Thomas Sun; Neil Maclean; Sean E Egan; Aaron D Schimmer; Alessandro Datti; Eldad Zacksenhaus
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.